Deal
| Published June 2, 2025

BioNTech and Bristol Myers Squibb sign monster deal

BioNTech and Bristol Myers Squibb have signed a global partnership to jointly develop and commercialize BioNTech's promising bispecific antibody BNT327. The agreement is worth up to USD 11,1 billion and...

Create account to read this article for free

Get free access to a limited number of articles.